Heterogeneity of androgen receptor content in advanced prostate cancer

Modern Pathology

Volumn 10, Issue 8, 1997, Pages 839-845

  Magi Galluzzi, Cristina ^a   Xu, Xiaowen ^a   Hlatky, Lynn ^a   Hahnfeldt, Philip ^a   Kaplan, Irving ^a   Hsiao, Pei Wen ^b   Chang, Chawnshang ^b   Loda, Massimo ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Androgen receptor; Image analysis; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR;

ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR DENSITY;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0030758487     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1993;43:7-26.
2. Coffey DS. Prostate cancer. An overview of an increasing dilemma. Cancer 1993;71:880-6.
3. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992;23:211-22.
4. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.
5. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma: early versus late endocrine therapy. Urol Clin N Am 1991;18:15-20.
6. Isaacs JT, Furuya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 1994;5: 391-400.
7. Zincke H. Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience. Semin Urol 1990;8:175-83.
8. Petrangeli E, Lubrano C, Ortolani F, Ravenna L, Vacca A, Sciacchitano S, et al. Estrogen receptors: new perspectives in breast cancer management. J Steroid Biochem Mol Biol 1994;49:327-31.
9. Parczyk K, Schneider MR. The future of antihormone therapy innovations based on an established principle. J Cancer Res Clin Oncol 1996;122:383-96.
10. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996;77:934-40.
11. Brendler CB, Isaacs JT, Follansbee AL, Walsh PC. The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. J Urol 1984;131:694-700.
12. Pertschuk LP, Macchia RJ, Feldman JG, Brady KA, Levine M, Kim DS, et al. Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up. Ann Surg Oncol 1994;1:495-503.
13. Fentie DD, Lackey WH, McBlain WA. Applicability of nuclear antigen receptor quantification to human prostatic adenocarcinoma. J Urol 1986;135:167-173.
14. Benson RC, Gorman PA, O'Brien PC, Holicky EL, Veneziale CM. Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer 1987;59:1599-606.
15. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991;67:3057-64.
16. van der Kwast ThH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991;48:189-93.
17. Sadi MV, Barrack ER. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 1993;71:2574-80.
18. Sadi MV, Barrack ER. Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumor progression after hormonal therapy. Cancer Surv 1991;11:195-215.
19. Pertschuk LP, Schaeffer H, Feldman JG, Macchia RJ, Kim YD, Eisenberg K, et al. Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 1995;73:302-5.
20. Ruizeveld de Winter JA, Janssen PJA, Sleddens HMFB, Verleun-Mooijman MCT, Trapman J, Brinkmann AO, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994;144:735-46.
21. Tilley WD, Lin-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinne JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 1994;54:4096-102.
22. Epstein JI. Prostatic intraepithelial neoplasia. In: Silverberg SG, editor. Prostate biopsy interpretation. 2nd ed. Philadelphia: Lippincott-Raven; 1995. p. 37-63.
23. Epstein JI. Grading of prostatic adenocarcinoma. In: Silverberg SG, editor. Prostate biopsy interpretation. 2nd ed. Philadelphia: Lippincott-Raven; 1995. p. 65-85.
24. American Joint Committee on Cancer. Prostate. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th ed. Philadelphia: Lippincott; 1992, p. 181-3.
25. Loda M, Fogt F, French FS, Posner M, Cukor B, Aretz HT, et al. Androgen receptor immunohistochemistry on paraffin-embedded tissue. Mod Pathol 1994;7:388-91.
26. Magi-Galluzzi C, Montironi R, Prete E, Kwan PWK, DeLellis RA. Effect of microwave oven heating times on androgen receptor antigen retrieval from paraffin-embedded prostatic adenocarcinoma. Anticancer Res 1996;16:2931-6.
27. Potter M. Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol Rev 1972;52:613-719.
28. Hlatky L, Tsionou C, Hahnfeldt P, Coleman CN. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res 1994;54:6083-6.
29. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Modeling of data. In: Press WH, Flannery BP, Teukolsky SA, Vetterling WT, editors. Numerical recipes in C: the art of scientific computing. Cambridge, England: Cambridge University Press; 1989. p. 548-57.
30. van der Kwast ThH, Têtu B. Androgen receptors in untreated and treated prostatic intraepithelial neoplasia. Eur Urol 1996;30:265-8.
31. Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 1993;24:298-310.
32. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992;147:798-803.
33. Gaddipati JP, McLead DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994;54:2861-4.
34. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:1541-50.
35. 24 213 18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994;198:74-80.
36. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-6.
37. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8.
38. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Chung LW, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
39. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-73.
40. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-8.
41. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994;86:1140-5.
42. Montironi R, Magi-Galluzzi C, Muzzonigro G, Prete E, Polito M, Fabris G. Effect of combination endocrine therapy (LHRH agonist and flutamide) in normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol 1994;47:906-13.
43. Nagle RB, Brawer MK, Kittelson J, Clark V. Phenotypic relationship of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol 1991;138:119-28.